| abstract |
pharmaceutical composition, and methods for treating a patient suffering from a neurodegenerative disorder and disease. The present invention features, inter alia, pharmaceutically acceptable compositions comprising metirapol as the pharmaceutically active agent alone; compositions comprising metyrapol and at least one additional pharmaceutically active agent; compositions wherein the hpa axis targeting agent is itself new or modified (e.g., a bispecific antibody designed to cross the blood-brain barrier or a redesigned compound known, for example, to conjugate to a substance passing through the blood-brain barrier) and compositions wherein the hpa axis targeting agent is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition may be formulated to include a dosage which It is too low to reduce plasma cortisol levels or formulated to preferably affect the skin. |